The Biden administration promises to increase vaccine delivery; the FDA issues an alert on alcohol-based hand sanitizers from Mexico; 3 pharma giants partner to speed EU vaccination efforts.
A delivery of 200 million more coronavirus disease 2019 (COVID-19) vaccine doses by the summer, on top of the 400 million already manufactured, is in the works by the Biden administration, The Washington Post reports. In addition, as early as next week—and lasting for 3 weeks—states could see a 16% bump in doses, from 8.6 to 10 million. By the end of March, Pfizer is promising to deliver 120 million additional doses of its vaccine, and Moderna, 100 million. Both have raised their yearly target doses, by 35% and 17%, respectively. Meanwhile, data on Johnson & Johnson’s 1-dose vaccine are expected within the week, which could help alleviate some of the concerns expressed by health officials about the current vaccine supply.
Citing possible methanol, or wood alcohol, contamination, the FDA yesterday issued an import alert on alcohol-based hand sanitizers manufactured in Mexico. The concern stems from products mislabeled as containing ethanol, or ethyl alcohol, when instead they test positive for the toxic and life-threatening agent methanol. According to FDA data, between April and December 2020, 84% of alcohol-based hand sanitizer samples for such products manufactured in Mexico failed to meet agency standards. Fourteen warning letters have been issued since June, with the most recent going to Laboratorios Jaloma S.A. de C.V. on Monday.
Sanofi will give BioNTech production access to a Frankfurt, Germany, plant in order to boost the EU supply of its COVID-19 vaccine by over 125 million doses, according to Bloomberg. The move comes as Sanofi has pushed back the expected delivery date of its own vaccine to summer 2021. Other manufacturing partnerships are in the works, too. Lonza Group AG (based in Switzerland), which manufactures Moderna’s vaccine, has expressed its willingness to offer similar assistance, and JCR Pharmaceuticals is gearing up to increase Japan’s AstraZeneca vaccine stockpile by 90 million doses.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More